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Abstract Muscle problems and other adverse symptoms as-
sociated with statin use are frequent reasons for non-
adherence and discontinuation of statin therapy, which results
in inadequate control of hyperlipidemia and increased cardio-
vascular risk. However, most patients who experience adverse
symptoms during statin use are able to tolerate at least some
degree of statin therapy. Given the profound cardiovascular
benefits derived from statins, an adequate practical approach
to statin intolerance is, therefore, of great clinical importance.
Statin intolerance can be defined as the occurrence of myalgia
or other adverse symptoms that are attributed to statin therapy
and that lead to its discontinuation. In reality, these symptoms
are actually unrelated to statin use in many patients, especially
in those with atypical presentations following long periods of
treatment. Thus, the first step in approaching patients with
adverse symptoms during the course of statin therapy is iden-
tification of those patients for whom true statin intolerance is
unlikely, since most of these patients would probably be ca-
pable of tolerating adequate statin therapy. In patients with
statin intolerance, an altered dosing regimen of very low doses
of statins should be attempted and, if tolerated, should gradu-
ally be increased to achieve the highest tolerable doses. In
addition, other lipid-lowering drugs may be needed, either in
combination with statins, or alone, if statins are not tolerated at
all. Stringent control of other risk factors can aid in reducing
cardiovascular risk if attaining lipid treatment goals proves
difficult.
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Introduction
Statins effectively decrease cardiovascular risk, and cholester-
ol lowering with statins has become a cornerstone of cardio-
vascular disease prevention for a wide range of patients [1].
Despite this, adequate use of statins is limited by adverse
symptoms in many patients [2–4], which leads to statin dis-
continuation in some patients, and low adherence to therapy in
others. The issue of statin intolerance is, therefore, of great
clinical importance.
Despite the existence of statin intolerance having been
widely acknowledged, a large degree of variability remains
as to what is considered to be statin intolerance. In addition,
there is significant uncertainty regarding the actual incidence,
and there is insufficient knowledge concerning the best thera-
peutic approaches to the problem. Most cases of statin intol-
erance are related to muscle complaints [5–7], with increased
liver or muscle enzymes [8], various neurological symptoms
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[9] and other problems being much less frequent. The glyce-
mic effects of statins are occasionally included as a symptom
of statin intolerance; although, they are undesired side effects
rather than serious findings necessitating discontinuation of
therapy in individual cases. Moreover, as we have previously
discussed elsewhere [10], the diabetogenic effects of statins
are generally overestimated.
It should be noted that all of the mentioned symptoms can
stem from a number of different causes and are often unrelated
to actual statin use. However, even among patients with true
statin-related symptoms, many can tolerate lower doses of the
same statin, or perhaps a different statin. Establishing a diag-
nosis of statin intolerance is therefore less straightforward than
it might appear, and an adequate therapeutic approach is more
complex than simple discontinuation of statin therapy.
As a result of these complexities, statin intolerance is cur-
rently gaining increased attention and several guidelines [5,
11, 12] and review papers [13–16] have recently been pub-
lished, thereby providing an in-depth discussion of this com-
plicated, and often controversial, topic. Practicing physicians,
however, may find the aforementioned recommendations
somewhat lengthy and difficult to implement in their daily
practice. In this review, we propose a practical definition of
statin intolerance and outline a therapeutic approach to pa-
tients with this condition.
Definition of Statin Intolerance
In general terms, statin intolerance can be defined as the oc-
currence of (1) adverse symptoms perceived by the patient to
be unacceptable, and/or (2) laboratory abnormalities suggest-
ing undue risk, which are attributed to statin therapy and lead
to its discontinuation. For practical purposes, descriptions re-
garding acceptability of symptoms, attributability to statin
therapy, and the degree of intolerance, need to be better
defined.
Most cases of statin intolerance are related to patient com-
plaints; the discontinuation of therapy due to laboratory ab-
normalities is far less common. Thus, in most cases, decisions
pertaining to statin intolerance are patient decisions. In this
context, it is important to note that some degree of adverse
symptoms might be tolerated by patients and it does not nec-
essarily imply intolerance of therapy. Statin intolerance is not
simply the occurrence of symptoms in general, but rather
those symptoms that are perceived to be unacceptable.
Hence, the patient’s subjective assessment of perceived risks
and inconveniences, versus the benefits of therapy, are at the
core of an effective approach to the issue of statin intolerance.
When experienced during the course of statin therapy, my-
algia and other adverse symptoms are often unrelated to treat-
ment, and most patients with a history involving episodes of
these symptoms are able to tolerate adequate statin therapy
[17, 18]. Identifying true cases of statin intolerance is,
therefore, of great practical importance in order to avoid un-
necessary discontinuation of statins from patients who would
otherwise benefit from them. However, evaluating the likeli-
hood that the adverse symptoms are causally related to statins
is often a difficult task (Table 1). Close temporal association to
statin therapy is an important feature that suggests causality.
Symptoms are more likely to be attributable to statins if they
appear within the first month of statin therapy, improve upon
discontinuation, and reoccur after readministration [3, 4].
Consequently, dechallenge–rechallenge testing is an impor-
tant evaluation tool when assessing statin intolerance.
Similarly, regional distribution and the type of pain/
complaints are important for assessing their association with
statin therapy. A causal relation to statins is more likely
in cases of symmetrical involvement of large muscle
groups (especially proximal lower limbs) or in cases
with widespread involvement; a causal relationship is
less likely when symptoms are asymmetrical or involve
small isolated regions. Typical complaints involve mus-
cle pain, tenderness or cramps, and weakness during
exertion, while joint or tendon pain, muscle tingling
and twitching, or shooting pain, suggest causes other
than statin therapy. In addition, factors known to be
associated with increased risk of statin intolerance, as
well as contributing factors that may precipitate symp-
tom manifestation, such as hypothyroidism [19], drug
interactions, and vitamin D deficiency [20], should be
carefully evaluated (Table 2). It is also important to rule
out conditions that are associated with symptoms that
mimic statin intolerance (musculoskeletal disorders, in
particular). The American College of Cardiology has
recently developed an ACC Statin Intolerance App to
aid clinicians in evaluating and managing patients who
report muscle symptoms while on a statin (available at
http://www.acc.org/StatinIntoleranceApp).
Given the specifications mentioned above, we propose the
following definition of statin intolerance for use in clinical
practice:
Statin intolerance is the occurrence of (1) adverse
symptoms perceived by the patient to be unacceptable,
and/or (2) laboratory abnormalities suggesting undue
risk, which are attributed to statin therapy and lead to
its discontinuation.
To be attributed to statins:
& symptoms or abnormalities should be temporally associ-
ated with the initiation of statin therapy, improve upon
discontinuation, and reoccur after the readministration of
therapy, and
& known precipitating factors and conditions with similar
presentations should first be excluded. These primarily
include musculoskeletal diseases, hypothyroidism, vita-
min D deficiency, strenuous exercise, intercurrent illness,
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or drug interactions (e.g., azole antifungals, macrolide an-
tibiotics, verapamil).
Regarding the degree of statin intolerance, it can be classi-
fied as partial or complete (additional information provided
below).
Mild symptoms should not be considered intolerance, pro-
vided they are deemed acceptable by the patient.
Among patients presenting with statin intolerance,
there is great variability regarding the number and doses
of statins they are unable to tolerate. Some patients are
intolerant of virtually all statins, even in low doses;
others only experience adverse symptoms with a partic-
ular statin, or only with the highest doses of particular
statins. With this in mind, we propose two degrees of
statin intolerance for consideration:
& complete statin intolerance: the inability to tolerate a min-
imum of three statins at their usual lowest daily starting
doses, and
& partial statin intolerance: the inability to tolerate statin
therapy in the form and dosages required to achieve treat-
ment goals (including the highest doses of potent statins, if
needed).
For the purposes of this definition, the lowest daily starting
doses of statins are proposed as rosuvastatin 5 mg, atorvastatin
10 mg, simvastatin 20 mg, lovastatin 20 mg, pravastatin
40 mg, fluvastatin 40 mg, and pitavastatin 2 mg.
Partial intolerance is pragmatically defined with respect to
the therapeutic needs of individual patients. Inability to toler-
ate some statins, or some doses, should not be considered as
statin intolerance, provided it does not interfere with the
achievement of treatment goals.
Therapeutic Approach to Statin Intolerance
Most patients who experience adverse symptoms when using
statins are able to tolerate at least one statin, albeit sometimes
only when administered in an altered dosing regimen. Given
the profound cardiovascular benefits of statins, statin therapy
remains the mainstay of lipid-lowering treatment for most of
these patients (Fig. 1).
In many patients, adverse symptoms are unrelated to statin
usage, especially in those with atypical and intermittent pre-
sentations following long periods of treatment. The first step
in approaching patients who experience adverse symptoms
during the course of statin therapy is therefore to assess wheth-
er the symptoms are likely attributable to statins. This in-
cludes obtaining a complete history of symptoms, evaluation
of risk factors for statin intolerance (Table 2), temporary with-
drawal of statins followed by a rechallenge, as well as seeking
other causes of the symptoms [5]. If statin intolerance appears
Table 1 Evaluating the likelihood of an association between muscle complaints and statin therapy
Causal relation of symptoms to statin therapy
Likely Unlikely
Regional distribution • symmetrical
• widespread or large muscle groups involvement (proximal
lower limbs, calves, proximal upper limbs)
• asymmetrical, unilateral
• small isolated regions
Characteristics
of the complaint
• muscle pain, tenderness, cramps, stiffness
• muscle weakness or heaviness during exertion
• shooting pain
• muscle tingling or twitching
• joint or tendon pain
Temporal association
to statin therapy
• symptoms appear within 4 weeks of initiation of statin • symptoms appear after >12 weeks of
initiation of statin
(appearance of symptoms within 4–12 weeks contributes marginally to the evaluation of causality)
Dechallenge/ rechallenge
testing
• symptoms improve within 4 weeks upon discontinuation of statin
• symptoms reoccur within 4 weeks after readministration of statin
• late or no improvement of symptoms upon
discontinuation of statin
• late or no reoccurrence after readministration
of statin
Adapted from [3, 4, 6]
Table 2 Factors associated with increased risk of statin intolerance
• History of muscular symptoms with other lipid-lowering therapies
• History of unexplained muscular symptoms
• History of unexplained creatine kinase elevation
• Family history of muscular symptoms with lipid-lowering therapy
• Strenuous exercise
• Hypothyroidism
• Vitamin D deficiency
• Drug interactions (gemfibrozil, macrolides, azole antifungals,
verapamil, amiodarone, protease inhibitors, cyclosporine)
• Advanced age
• Female gender
• Low body mass index
• Alcohol abuse
Adapted from [3, 11]
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unlikely, the patient can probably tolerate adequate therapy
with the same, or alternative, statin.
Likewise, potential provoking factors such as hypothyroid-
ism, vitamin D deficiency, or drug interactions should also be
evaluated, as correcting these problems may improve statin
therapy tolerance.
In patients with statin intolerance, very low doses of statins
administered via an altered dosing regimen should be
attempted and, if tolerated, should be gradually increased to
achieve the highest tolerable doses. With this cautious ap-
proach, the majority of patients are able to tolerate at least
some degree of statin therapy. In addition, other lipid-lower-
ing drugs may be needed to achieve the appropriate targets.
The principles of lipid-lowering therapy in cases of statin in-
tolerance are discussed in the following sections.
Lifestyle interventions reduce blood cholesterol levels and
improve other cardiovascular risk factors, but adherence to
these measures is low among the general patient population.
Encouraging and motivating patients to improve adherence to
lifestyle measuresmay aid in the attainment of treatment goals
in cases where the possibility of using lipid-lowering drugs is
limited.
The ultimate goal of lipid-lowering treatment is to decrease
cardiovascular risk, which depends upon the interplay of mul-
tiple risk factors. Control of other risk factors—especially
those of hypertension and smoking—effectively reduces car-
diovascular risk, which may move the patient to a lower risk
category with less stringent, and more easily attainable, lipid
goals.
Coenzyme Q10 (CoQ10) supplementation is frequently
used for statin myalgia, but the evidence in support of its use
has, thus far, been contradictory. Recently, a well-designed
trial [21], in conjunction with a meta-analysis of previous
smaller trials [22], consistently failed to demonstrate a
symptoms resolve
Patient with muscle complaints on his/her first statin
Discontinue statin
Discuss with the patient the issue of statin muscle side effects and explain the need for trying another statin(s)
Search for potential provoking factors and correct 
as appropriate
Perform de-challenge/re-challenge testing
Continue with therapy or gradually increase the 
doses, if appropriate, to achieve the highest 
tolerable dose
Try another statin at the lowest starting dose, 
including re-challenge testing if appropriate
this step may be repeated in case of intolerance
Try very low doses of statin using non-daily 
dosing, preferably atorvastatin or rosuvastatin 
this step may be repeated in case of intolerance
Initiate non-statin therapy Gradually increase the doses to achieve the highest 
tolerable dose
Add non-statin therapy if indicated
Continue with therapy or gradually increase the 
doses, if appropriate, to achieve the highest 
tolerable dose
Continue with therapy or gradually increase the 
doses if appropriate to achieve the highest 
tolerable dose
symptoms reappear no symptoms
symptoms persist
symptoms reappear no symptoms
symptoms reappear no symptoms
symptoms reappear no symptoms
Search for other causes of the symptoms and treat 
accordingly
Try another statin at the lowest starting dose
Fig. 1 Flowchart for evaluation and management of patients with statin-associated muscle complaints
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difference between CoQ10 and placebo, demonstrating that
the beneficial effect of CoQ10 supplementation in patients
with statin-induced myalgia is quite unlikely.
Statin Therapy
In patients with partial statin intolerance (i.e., those who re-
quire, but are unable to tolerate, moderate or high doses of
potent statins), lower doses, or less potent statins, should be
used.
For patients unable to tolerate any statin at the usual
starting daily dose, there is emerging agreement that
very low doses, and/or less-than-daily dosing, should
be attempted [7, 13]. Since the association between stat-
in dose and low-density cholesterol (LDL-C) is logarith-
mic, reducing the usual dose of a statin to one-half (or
even to one-quarter) still provides a reasonable degree
of lipid lowering (ultimately, this approach is simply
applying the notorious Brule of six^ in the reverse di-
rection). Multiple studies of patients with hypercholes-
terolemia have demonstrated that rosuvastatin 5–10 mg
or atorvastatin 10–20 mg given every other day pro-
duced LDL-C reduction of 20–40 % [7]. In patients
with previous statin intolerance, rosuvastatin adminis-
tered once or twice weekly (at a mean dose of 10 mg
per week) achieved an LDL-C reduction of 23–29 %
and was well tolerated by 74–80 % [23–25] of patients.
In a recent review report from a specialized lipid clinic,
90 % of patients referred for intolerance to multiple
statins were actually able to tolerate statin therapy, al-
though the majority was at a reduced dose and less-
than-daily dosing [26]. Obviously, the efficacy of non-
licensed dosing regimens in terms of reducing cardio-
vascular risk has not been studied. On the other hand,
most statin effects are mediated through the lowering of
LDL-C; therefore, it would seem reasonable to assume
that the cardiovascular risk reduction achieved with al-
ternate statin dosing regimens would be proportionate to
their LDL-lowering effects.
In terms of a practical approach to statin intolerance, listen-
ing to the patient’s complaints and fears is crucial to encourage
greater receptivity and willingness to try various statins and
dosing schedules, some of which may be associated with ad-
verse symptoms [5, 26]. These patients need to understand
that (i) while these symptoms may be bothersome, they are
rarely dangerous, and (ii) they are free to discontinue the drug
at any time. It is equally important that physicians emphati-
cally explain the beneficial effects of therapy in terms of car-
diovascular event reduction.
In order to prevent unnecessarily intense symptoms
of statin intolerance and improve patient adherence to
statin therapy in the general population, it may be wise
to initiate statin therapy in statin-naive patients with low
or moderate (rather than high) doses in the majority of
cases, except for patients at highest cardiovascular risk.
Patients who previously tolerated lower doses are much
more willing to return to them in cases where they
experienced problems with higher doses, compared to
those who were intolerant to a higher starting dose. It
is also advisable to perform both creatine kinase and
liver tests prior to commencing statin therapy in order
to establish reference baseline values in case the patient
develops elevations in these tests during therapy.
Non-statin Lipid-Lowering Drugs
Other lipid-lowering drugs may be needed to achieve
appropriate targets, either in combination with statins,
or alone, if statins are not tolerated at all. A combina-
tion of these drugs and low-dose statin therapy can pro-
vide reductions in LDL-C similar to those obtained with
high doses of statins.
Ezetimibe decreases LDL-C by 15–20 % (either in combi-
nation with statins or as monotherapy) and is widely used in
patients with statin intolerance. Ezetimibe is well tolerated,
but the evidence of cardiovascular benefit is limited to one
trial that demonstrated a modest 6 % reduction of cardiovas-
cular events [27].
Fibrates are primarily used to lower triglycerides and in-
crease high-density cholesterol; they also decrease LDL-C
levels, but to a lesser extent. The effect on LDL-C is more
pronounced in patients with hypertriglyceridemia.
Accordingly, the reduction of cardiovascular risk with fibrates
is only 10 % in unselected patient population, but is substan-
tially greater (≈30 %) in patients with hypertriglyceridemia
[28]. As such, fibrates represent a reasonable option in these
patients. However, caution must be exercised when combin-
ing fibrates with statins, as the combination may increase the
risk of myalgia.
Bile acid sequestrants (resins) provide LDL-C reduction
that is comparable to that observed with ezetimibe, and they
have been proven to reduce cardiovascular events. Resins are
safe, but poorly tolerated, due to gastrointestinal side effects.
The recently developed colesevelam has fewer side effects
and better patient compliance.
Niacin is similar to fibrates relative to its effect on blood
lipids, but its use in clinical practice has dropped substantially
after two clinical-endpoint trials failed to demonstrate cardio-
vascular benefits of niacin therapy [29, 30].
PCSK9 inhibitors are a novel class of lipid-lowering drugs;
they were approved quite recently in the USA and Europe.
They reduce LDL-C levels by≈50 %. Meta-analyses of phase
2 and 3 trials demonstrated a >50 % reduction of cardiovas-
cular events with evolocumab and alirocumab [31, 32], and
the results of major clinical trials are eagerly awaited by
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clinicians. Statin intolerance is one of the approved indications
for use of PCSK9 inhibitors.
Conclusions
Muscle problems and other adverse symptoms associatedwith
statin use are relatively frequent reasons for non-adherence
and discontinuation of statin therapy, which can contribute
to adverse cardiovascular outcomes. However, most patients
who experience objectionable symptoms during statin use are
still able to tolerate at least some degree of statin therapy. The
clinician’s challenge is therefore to help their patients find
their way back to statins.
In essence, this task comprises only a few steps: First, iden-
tify patients with unlikely statin intolerance, and who can
therefore probably continue with some type of adequate statin
therapy. A pragmatic definition of statin intolerance, as
outlined above, may be useful in this respect. Second, in cases
with statin intolerance, consider very low doses of statins and/
or altered dosing regimens. In addition, other lipid-lowering
drugs may be needed, in conjunction with changes in lifestyle
and better control of other cardiovascular risk factors. With this
cautious and multifactorial approach, reasonable improvement
in blood lipid levels, as well as a marked reduction in global
cardiovascular risk score, can be achieved in most patients.
As simple this approach may appear, it may prove difficult
in practice. Listening to patients’ complaints and fears,
explaining the benefits of therapy, and motivating patients to
try various therapeutic schedules (some of which may be as-
sociated with adverse symptoms) are often difficult and time-
consuming tasks. From a clinician’s perspective, a successful
approach to statin intolerance primarily entails the art of suc-
cessful communication with the patient.
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